MedPath

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Phase 1
Completed
Conditions
Pharmacodynamics of ASP1707
Pharmacokinetics of ASP1707
Interventions
Drug: ASP1707 multiple dose of dose levels 1-4
Drug: ASP1707 parallel multiple dose of dose levels 1-3
Drug: ASP1707 single dose of dose levels 1 -7
Drug: Placebo single dose of dose levels 1-7
Drug: ASP1707 single dose fasted
Drug: ASP1707 single dose fed
Drug: Placebo multiple dose of dose levels 1-4
Drug: Placebo multiple dose of dose levels 1-2
Drug: ASP1707 multiple dose of dose levels 1-2
Drug: Placebo parallel multiple dose
Registration Number
NCT02368912
Lead Sponsor
Astellas Pharma Europe B.V.
Brief Summary

This study consists of four parts:

Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy young male subjects to evaluate the safety, tolerability pharmacokinetics (PK) and effect on certain hormones and if possible to determine the highest well-tolerated dose of ASP1707 in healthy young male subjects under fasted conditions.

Part 2 is an open label, randomized crossover, single dose study to determine the effect of food on the pharmacokinetics of ASP1707and effect on certain hormones in healthy young male subjects.

Part 3 is a randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PK) of ASP1707 in healthy elderly men and healthy premenopausal females, and to determine the effect on certain hormones in males. Age and gender is also evaluated.

Part 4 is a randomized, double-blind, placebo-controlled, parallel, multiple dose study to evaluate the safety, tolerability and PK of ASP1707, and its effect on certain hormones in healthy pre-menopausal female subjects.

Detailed Description

Part 1 comprises 7 dose groups of 8 healthy young male subjects. ASP1707 or matching placebo ( 3 to 1 ratio) is given as a single dose under fasted conditions.

The first group receives the lowest dose while the last group receives the highest dose.

Part 2 (Food-Effect) The group consists of 12 healthy young male subjects who receive two separate doses of ASP1707 under fasted or fed conditions. Half of the subjects are dosed first under fasted condition and half of them had first an FDA high-fat breakfast. Subjects receive the alternate treatment on the second occasion. Dosing is separated by at least 7 days or 7 times t1/2 (terminal elimination half-life) as assessed from Part 1.

Part 3 Comprises 4 dose groups of 12 healthy elderly men each, and two groups of 12 healthy premenopausal women. The latter are dosed ASP1707 or placebo in parallel to the 4 male groups. Subjects are fasted or fed depending on observations from Part 2.

Dose levels are defined after evaluating interim safety, tolerability and PK and PD results from Part 1. A lower maximum dose is used in women than in men, based on preclinical data. Dose escalation in the men is independent from dose escalation in the women. Women and men receive once-daily dosing;

Part 4 includes 4 groups, 1 placebo and 3 for ASP1707, each with 9 pre-menopausal women. Subjects in each dose group receive a fixed daily dose. Subjects are domiciled for various intervals during each of 3 menstrual cycles. Dosing occurs for 21 Days during the subjects' second menstrual cycle of the study (Day 1 of Period 2); fasted or fed depending on observations from Part 2.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
176
Inclusion Criteria

Parts 1 & 2:

  • Healthy young male subject aged 18 to 45 years inclusive
  • Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
  • Male subjects must be non-fertile, or must practice an adequate contraceptive method to prevent pregnancies.

Part 3:

  • Healthy elderly male subject aged 55 years or older, or healthy pre-menopausal female subject aged 18 to 45 inclusive.
  • Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
  • Male subject must be non-fertile, or must practice adequate contraceptive methods.
  • Female subjects must be of non-child bearing potential, i.e. surgically sterilized or practice adequate (double barrier) non-hormonal contraceptive methods.

Part 4:

  • Healthy pre-menopausal female subject aged 18 to 45 inclusive.
  • Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
  • Female subjects must be of non-child bearing potential, i.e. surgically sterilized or practice adequate contraceptive methods.
  • Females having a regular menstruation cycle with a duration between 25 up to 30 days.
Exclusion Criteria

Parts 1 & 2:

  • Male subjects with out-of-range Testosterone levels in serum at screening.
  • Subjects with any history of cancer.
  • Any of the liver function tests (i.e. ALT and AST) above the upper limit of normal.
  • A QTc interval of > 430 ms after repeated measurements.
  • Regular use of any inducer of metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
  • Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.

Part 3:

  • Pregnancy within 6 months before screening assessment or breast feeding 3 months before screening.
  • Male subjects with out-of-range T levels in serum at screening.
  • Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.

Part 4:

  • Pregnancy within 6 months before screening assessment or breast feeding 3 months before screening.
  • Use of any hormonal interfering contraceptives in the 3 months before admission (for 3 consecutive menstruation cycles) OR any evidence of unovulatory menstrual cycles.
  • Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4ASP1707 multiple dose of dose levels 1-4healthy elderly male
9. Parallel multiple dose, ASP1707 dose levels 1-3ASP1707 parallel multiple dose of dose levels 1-3healthy pre-menopausal female
1. Single ascending dose (SAD), ASP1707 dose levels 1-7ASP1707 single dose of dose levels 1 -7healthy young male
2. Single ascending dose (SAD), placebo dose levels 1-7Placebo single dose of dose levels 1-7healthy young male
3. Food effect (FE), ASP1707 fastedASP1707 single dose fastedFasted healthy young male
4. Food effect (FE), ASP1707 fedASP1707 single dose fedFed healthy young male
6. Multiple ascending dose (MAD), Placebo, dose levels 1-4Placebo multiple dose of dose levels 1-4healthy elderly male
8. Multiple ascending dose (MAD), Placebo dose levels 1-2Placebo multiple dose of dose levels 1-2healthy pre-menopausal female
7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2ASP1707 multiple dose of dose levels 1-2healthy pre-menopausal female
10. Parallel multiple dose, PlaceboPlacebo parallel multiple dosehealthy pre-menopausal female
Primary Outcome Measures
NameTimeMethod
PD of ASP1707 - Time of offset therapeutic rangePre-dose to Day 26

Part 4, period 2. E2 levels

Safety assessed by nature, frequency and severity of adverse eventsScreening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)

Respectively Part 1 and Part 3

PK of ASP1707 measured by time to reach quantifiable concentrations (tlag) in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by Cmax in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by amount excreted unchanged into urine (Ae) from time of dosing until last measurable concentration (Aelast) in urinePre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by Ae in % extrapolated to time infinity (Aeinf%) in urinePre-dose (Day 1) to Day 5

Part 2

Safety assessed by physical examinationScreening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)

Respectively Part 1 and Part 3

Safety assessed by safety laboratory testsScreening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)

Respectively Part 1 and Part 3, Biochemistry, hematology, and urinalysis

Safety assessed by 12 lead electrocardiogram (ECG)Screening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)

Respectively Part 1 and Part 3

Safety assessed by vital signsScreening to End of Study Visit (ESV) (up to Day 19 and up to Day 39)

Respectively Part 1 and Part 3. Vital signs include blood pressure and pulse.

Pharmacokinetics (PK) of ASP1707 measured by area under the plasma concentration - time curve (AUC) extrapolated to time = infinity (AUCinf) in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by time to attain maximum concentration (tmax) in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by renal clearance (CLR) in urinePre-dose (Day 1) to Day 5

Part 2

Safety assessed by continuous cardiac monitoring (Holter)Days -1 and 21

Part 3

PD of ASP1707 - maximal duration within therapeutic rangePre-dose to Day 26

Part 4, period 2. E2 levels

PK of ASP1707 measured by area under the plasma concentration-time curve (AUC) to time from the time of dosing to the last measurable concentration (AUClast) in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by terminal elimination half-life (t1/2) in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by apparent volume of distribution (Vz/F) in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by apparent clearance (CL/F) in plasmaPre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by Ae extrapolated to time = infinity (Aeinf) in urinePre-dose (Day 1) to Day 5

Part 2

PK of ASP1707 measured by Ae in % up to the collection time of the last measurable concentration (Aelast%) in urinePre-dose (Day 1) to Day 5

Part 2

PD of ASP1707 measured by average concentration (Cavg, day 7-15) in plasmaPre-dose to Day 26

Part 4, period 1, 2 and 3. E2, FSH and LH levels

PD of ASP1707 measured by average concentration (Cavg, day 23-26) in plasmaPre-dose to Day 26

Part 4, period 2. E2, FSH and LH levels

PD of ASP1707 - Time of onset therapeutic rangePre-dose to Day 26

Part 4, period 2. E2 levels

Pharmacodynamics (PD) of ASP1707 measured by Cmax in plasmaDay -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3

Part 4, period 1, 2 and 3. Estradiol (E2), Follicle-stimulating hormone (FSH) and Luteinizing Hormone (LH) levels

PD of ASP1707 measured by tmax in plasmaDay -1 to day 15 for period 1, Day 7 to Day 15 for periods 2 and 3

Part 4, period 1, 2 and 3. E2, FSH and LH levels

PD of ASP1707 measured by average concentration (Cavg, day 5-19) in plasmaPre-dose to Day 26

Part 4, period 3. E2, FSH and LH levels

PD of ASP1707 - Time of start menstruation after last dose of study drugPre-dose to Day 26

Part 4, period 3

PD of ASP1707 - total duration within therapeutic range (20-50 pg/mL)Pre-dose to Day 26

Part 4, period 2. E2 levels

Secondary Outcome Measures
NameTimeMethod
PK profile of ASP1707 in plasma and urine for Part 4Pre-dose (Day 23) to Day 25

AUCtau, tmax, Cmax, t1/2, Vz/F, CL/F, CLR, Ctrough, PTR, Aetau, Aetau%,

PD profile of ASP1707 for Part 3Pre-dose (Day 1) to Day 39

T, LH and FSH levels: Cmin, tmin, maximal %Reduction T only: Number and percentage of subjects with T \< 0.5 ng/mL at any time post-first dose, Number and percentage of subjects with T \< 0.5 ng/mL after last dose, Number of subjects reaching T\<0.5 ng/mL for ≥14 days, Day of onset of T \< 0.5 ng/mL after multiple doses of ASP1707 (T \< 0.5 ng/mL for the first time), Time of onset of T \< 0.5 ng/mL after first dose, Duration of T \< 0.5 ng/mL after single dose and during multiple dosing, Total duration, Maximal duration:Time from last dose to return to baseline levels for T, LH and FSH, Duration of T \< 0.5 ng/mL after last dose

Safety profile assessed by nature, frequency and severity of adverse events, physical examination, vital signs, safety laboratory tests and 12 lead ECGScreening to End of Study Visit (ESV) (Up to 31 days and up to 62 days)

Respectively Part 2 and Part 4

PK profile of ASP1707 in plasma and urine for Part 3Pre-dose (Day 1) to Day 25

AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR, Ctrough, AUC during the time interval between consecutive dosing (AUCtau), Accumulation Ratio (Rac), Peak Trough Ratio (PTR), Ae during the time interval between consecutive dosing (Aetau), Aetau as percentage of total dose (Aetau%), Ae during the time interval between consecutive dosing (AUCtau), (AUC0-24h), Ae0-24h, Ae0-24h%

PD profile of ASP1707 for Part 1 and Part 2Pre-dose (Day 1) to Day 12-19

Testosterone (T), LH and FSH levels: Cmin, tmin, maximal %Reduction and T only: Number and percentage of subjects with T castration level (= T \< 0.5 ng/mL) after single dose, Time of onset of T \< 0.5 ng/mL after single dose, Duration of T \<0.5 ng/mL after single dose

PK profile of ASP1707 in plasma and urine for Part 1Pre-dose (Day 1) to Day 5

AUCinf, AUClast, tlag, tmax, Cmax, t1/2, Vz/F, CL/F, Aelast, Aeinf, Aelast%, Aeinf%, CLR

Trial Locations

Locations (1)

SGS Life Science Services, Aster

🇫🇷

Paris, France

Related Trials

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy